메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
김미 (충남대학교 의과대학 Department of Surgery Chungnam National University College of Medicine Daejeon Korea) 이진선 (충남대학교 의과대학 Department of Surgery Chungnam National University College of Medicine Daejeon Korea)
저널정보
한국유방암학회 Journal of Breast Disease Journal of Breast Disease 제5권 제2호
발행연도
2017.12
수록면
39 - 45 (7page)
DOI
10.14449/jbd.2017.5.2.39

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: Both the incidence of breast cancer as well as, the number of patients with metastatic breast cancer has increased. Taxane and anthracycline chemotherapy is known to be effective in metastatic breast cancer; however, the subsequent treatment option when such treatment fails remains unestablished. The aim of the present study was to analyze the effect and response of cisplatin and etoposide treatment along with the predictive factor for patients who failed taxane and anthracycline chemotherapy for metastatic breast cancer. Methods: Forty-three patients with breast cancer whose regimen was changed to cisplatin and etoposide chemotherapy from taxane and anthracycline chemotherapy owing to treatment failure were included in this study. The chemotherapy regimen consisted of intravenous injection of 100 mg/m2 etoposide and 70 mg/m2 cisplatin on day 1 and then intravenous injection of 100 mg/m2 etoposide on days 2 and 3. This cisplatin and etoposide chemotherapy was repeated at 3 week intervals, and patients were assessed after the 2nd or 3rd cycle of therapy to evaluate the tumor response. Results: The average cycle and progression-free survival of cisplatin and etoposide chemotherapy were 4±3.1 (range, 1?16) and 12±14.2 weeks (range, 0?60 weeks), respectively. The average overall survival was 44±33.9 months (range, 11?149 months). The treatment response group consisted of 23 patients (53.5%) who continuously received cisplatin and etoposide chemotherapy for over four cycles, while the non-response group consisted of 20 patients (46.5%) who underwent three or fewer cycles of chemotherapy. Patients with excellent response to cisplatin and etoposide chemotherapy also showed good response to taxane and anthracycline chemotherapy (p=0.011). Conclusion: In patients who show good response to taxane and anthracycline chemotherapy, cisplatin and etoposide chemotherapy is also expected to have a positive result.

목차

등록된 정보가 없습니다.

참고문헌 (4)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0